ArteraAI, a Los Altos-based startup, has raised $90 million in funding from a group of investors led by Rill Data, Google, and Salesforce.org. Other investors include Coatue, Koch Disruptive Technologies, Johnson & Johnson, Walden Catalyst Ventures, Breyer Capital, Factory, Hazel Health, LA Clippers, and Stanford University.

The startup uses artificial intelligence (AI) to develop personalized treatment options for localized prostate cancer. Its AI technology uses prognostic and predictive biomarkers developed through five phases III randomized trials to predict patient outcomes and personalize treatment plans.

With this new funding, ArteraAI plans to develop further and expand its AI platform and conduct additional clinical trials. The company also intends to work with healthcare providers to integrate its technology into clinical practice and to help more patients receive personalized treatment for prostate cancer.

Prostate cancer is the second most common cancer in men worldwide. Moreover, there is a critical need for better, more personalized treatment options. ArteraAI's AI technology has the potential to revolutionize prostate cancer treatment by providing customized treatment plans. It tailors each patient's unique needs and characteristics.

The company's groundbreaking approach to cancer treatment has attracted significant attention from investors and the medical community. With this new funding, ArteraAI is poised to make significant strides in personalized cancer treatment and to help more patients. They receive the care they need to beat prostate cancer. Visit us for more information about their latest funding round: https://founderlodge.com/round/ArteraAI-raises-90000000-Unknown-2023-03-27-Andre-Esteva-MTE0OTA.